PG"3 is a new monoclonal antibody (MoAb) specifically directed against a peptide sequence located in the aminotermina1 region of the human PML protein. PML gene fuses with the retinoic acid receptor a (RARa) gene during the t(15; 17) chromosomal translocation of acute promyelocytic leukemia (APL). The epitope recognized by PG-M3 is speciesspecific and fixative-resistant and is shared by most PML isoforms and PMLIRARa fusion proteins. PML is consistently located within the nucleus, although a minority of cells (about 20%), both in vitro and in vivo, show positivity for PML also in the cytoplasm. The nuclear staining pattern of PG"3 varies from speckled (cells other than APL) to micropunctate (APL cells). Although two physiologically expressed PML isoforms are detectable by immunocytochem-CUTE PROMYELOCYTIC leukemia (APL), the M3 subtype of the French-American-British (FAB) classification,' is characterized by a reciprocal translocation that involves the PML gene on chromosome 15 and the retinoic acid receptor a (RARa) gene on chromosome 17.'-6 Two fusion genes are formed as a consequence of the translocation: the PMWRARa gene on the recombinant 15q+ chromosome and its reciprocal RARaPML gene on the recombinant 17q-chromosome?-" The most likely candidate for the transforming gene is PMURARa, as it is expressed in 100% of APL cases, whereas RARaPML is expressed in only 70% to 80% of cases?-13 Support comes from the fact that, in vitro, PMLRARa blocks terminal differentiation of hemopoietic precursor cell lines and promotes cell growth by inhibiting apoptotic cell death.14 The PML/RARa fusion protein retains most of the presumed functional domains of the wild-type PML and RARa proteins and the potential to interfere with endogenous signaling pathways of both PML and R A R L Y .~.~ Understanding the mechanism of action of the PMLJRARa fusion protein requires knowledge of the function of the normal RARa and PML proteins. RARa is a member of the superfamily of nuclear hormone receptors that are involved in fundamental biologic processes, such as development and differentiati0n,6.'~.'~ The function of the normal PML protein is unknown. Although immunohistologic studies have been of great value in outlining the potential functional role of certain proteins (eg, the bc12 oncogene product)," there is only limited information on tissue distribution of the normal PML protein. PML is mainly localized in the nucleus with a typical speckled pattern.'*-'' Expression of the PML protein has been investigated only in cytologic preparations of bone marrow, where PML appears to be expressed mainly on cells of the myeloid lineage.'* Extensive immunohistologic studies on tissue sections have been hindered by the fact that only polyclonal antibodies against the PML protein are available. These reagents are usually associated with high levels of tissue background staining and are available in limited amounts?' This prompted us to produce a monoclonal antibody (MoAb) against PML by immunizing Balb/c mice with a small peptide sequence located close to the cysteinehistidine-rich region (putative DNA binding domain) of the PML protein. We then performed detailed studies on the localization pattern of PML in cell lines, PML-transfected cells, and normal and pathologic human tissues.
This prompted us to produce a monoclonal antibody (MoAb) against PML by immunizing Balb/c mice with a small peptide sequence located close to the cysteinehistidine-rich region (putative DNA binding domain) of the PML protein. We then performed detailed studies on the localization pattern of PML in cell lines, PML-transfected cells, and normal and pathologic human tissues.
MATERIALS AND METHODS

Production of anti-PML antibodies.
A synthetic peptide corresponding to amino acids 37 to 5 1 of the PML protein [PSPSYIERA-PASEEE (C)-NH2,23 Fig l] was synthesized by solid-phase techniques and coupled with keyhole limpet hemocyanin (KLH)." Balb/c mice were immunized intraperitoneally with the peptide-KLH conjugate (200 pg per injection) plus Freund's adjuvant three times at intervals of 10 days. The booster was performed by injecting the peptide-KLH conjugate (300 pg) intravenously, and the fusion was performed 3 days later, as de~cribed.2~ The screening was performed by the immunoalkaline phosphatase (APAAP) techniquez6 on tonsil cryostat sections and cytospins of the U937 cell line. Supernatants from wells that gave nuclear labeling (the expected location site of 2,3, and 4) . The serinelproline-rich (SIP) domain that contains putative phosphorylation sites is indicated. The non-coiled-coil portion of the a-helix is of variable length in the different PML isoforms (borders of the portions that lack the various isoforms are numbered). NLS, nuclear localization signal. Asterisk (") indicates the location of the amino acid sequence recognized by the PG-M3 MoAb.
human cDNA encoding full-length PML protein. Cloning of the selected hybridoma was performed by a limiting dilution technique in flat bottom, 96-well plates.
Rabbits were immunized with the same peptide-KLH conjugate at intervals of 2 weeks. Antipeptide antibodies were affinity-purified from the sera on a Sepharose-bovine serum albumin (BSA)-peptide column.
Expression of PML and PMURARa cDNAs in COS-l, PA 317, NIH-3T3. and 11937 cells. The PML3 3-4-6-7 cDNA (Fig I ) was cloned into the EcoRI restriction site of the pMT2 expression v e~t o ?~ to obtain the pMT2-PML3 cDNA. For transient expression experiments, COS-l cells were cultured in Dulbecco's modified Eagle's medium in the presence of 10% bovine calf serum and transfected with 5 pg of pMT2-PML3 or control pMT2 DNA by diethyl aminoethyl (DEAE)-dextran technique.I4
The PML3 3-4-6-7 cDNA and cDNAs representative of different PML isoforms (PML2 3-4-5-6-7, PML 3-4-7, and PML3 3-7; Fig  I ) were cloned into the EcoRI site of the LXSN retroviral vectoi' and transfected into NIH-3T3 cells by the calcium-phosphate technique." NIH-3T3 transformants were obtained by 800 pglmL G418 selection, and PML-overexpressing clones were selected by Western blotting analysis with specific anti-PML polyclonal antibodies.
The different PML isoform cDNAs (PML2 3-4-5-6-7, PML3 3-4-6-7, PML 3-4-7, and PML 3-7) were inserted into U937 cells by retrovirus-mediated gene transfer, as previously de~cribed.'~ To express the PMLlRARa protein in NIH-3T3 cells, the PMU RARa cDNA was cloned into the MT-I plasmid (MT-I-PR), under the control of the inducibile metallothionine I promoter. NIH-3T3 cells were transfected with the MT-PR-I plasmid and G418-selected in the absence of zinc to obtain transformant clones. Individual clones were then treated with zinc to induce PMURARa expression and analyzed by Western blotting with a polyclonal anti-RARa antibody.'" COS-l and U937 transfected cells were cytocentrifuged, and NIH-3T3 transfected cells were prepared in Lab-Tek tissue culture chambedslides (Miles Laboratory, Naperville, IL)." Cells samples were then dried overnight, fixed in acetone for 10 minutes, and subjected to immunostaining proced~re.'~ Cell lines. A number of cell lines of different origin (human: MOLT-4, Daudi, L-428, Cole, JB6, K-562, U937, HL60, KGI, NB4, and HeLa; mouse: NIH-3T3, NSO, EU4, BL6, and L5178Y; monkey: COS-l) were tested for their reactivity with FGM3 on cytospins prepared from exponentially growing cells. Cytospins were processed for immunocytochemical studies as described above."
Cell activation and differentiation experiments.
Activation of U937 cells was induced by incubation with interferon y (IFN-y) (200 U/mL). For differentiation experiments, the promonocytic U937 cells were plated in fresh medium [RPMI 1640 containing 10% fetal calf serum (FCS)] at a density of 2.5 X IOs/mL and were grown for 7 days in the absence of inducers (control) or in the presence of 250 nglmL vitamin D3 (Hoffman-La Roche, Basel, Switzerland) and/or 1 ng/mL transforming growth factor p1 (TGFpl; ICN Biomedicals, Milan, I t a l~) .~" In some experiments, U937 cells were both activated and induced to mature after incubation with IFN-y (200 UlmL) plus vitamin D3 (200 ng/mL) plus TGFpl ( 1 ng/mL). Cells were then harvested, cytocentrifuged, and tested for changes in morphology, phenotype, and PML expression. Maturation of cells was assessed by APAAP immunostaining with MoAbs directed against monocytelmacrophage restricted antigens: Leu-M3 (CD14). Ros-63 (CD1 IC), PG-MI (CD68)," and PGM2 (unclustered)." MoAbs directed against the CD3 and CD8 antigens served as negative controls, and Dako LC (anti-CD45) was used as positive control. The percentage of proliferating cells was assessed with the Ki-67 MoAb."
Tissue specimens. Samples from a variety of normal and pathologic human tissues collected for diagnostic purposes were studied for their reactivity with PG-M3. Normal tissues from different animals (calf, lamb, swine, dog, cat, rabbit, mouse, rat, chicken, and pigeon) were obtained from the Department of Veterinary Pathology, Perugia University (Perugia, Italy).
All human and animal tissue samples were obtained fresh and were divided in two pieces. One portion of the tissue was fixed in formalin (overnight) or B5 (2 to 3 hours) and embedded in paraffin for routine histology and immunostaining with PG"3 on paraffin sections after microwave heating." The other piece was snap-frozen in liquid nitrogen and cut in a cryostat to achieve 5-pm frozen sections that were air-dried overnight, fixed in acetone for IO minutes, and either immunostained immediately with PGM3 or stored at -20°C until immunostaining.2' Single and double immunoenzymatic labeling. All cytologic and tissue samples were stained by the immunoalkaline phosphatase (APAAP) technique, as previously described." The alkaline phosphatase reaction was revealed by the new Fucsin substrate. 26 The endogenous alkaline phosphatase was blocked by adding levamisole to the substrate solution at the final concentration of I mm~l/L.'~ Slides were then counterstained for 5 minutes in Gill's hematoxylin and mounted in Kaiser's gelatin. Double immunoenzymatic staining was performed as described previously."6 Briefly, frozen sections from normal thymus were incubated with MoAbs directed against intermediate cytokeratin filaments (Dako MNFll6) or macrophage-restricted antigens,"," followed by a peroxidase-conjugated goat-antimouse Ig (Dako, Glostrup, Denmark). The peroxidase reaction was developed using a diaminobenzidine/HzOz substrate. After three washes in Tris-buffered saline (TBS), the PG"3 antibody was added, and the immuno- The total lysates and the immunoprecipitates were loaded onto an 8% sodium dodecyl sulfate (SDS)-acrylamide gel and electrotransferred to nitrocellulose ~heets.2~ Nitrocellulose sheets were blocked in TBS-T buffer plus 5% nonfat powdered milk and then incubated for 3 hours at room temperature with the polyclonal anti-PML antibody diluted 1:500. After extensive washing in TBS-T buffer, the blots were incubated for 30 minutes with an alkaline phosphatase-conjugated, antirabbit antibody and then stained by using the NBTBCIP substrate.
RESULTS
Production and speciJicity of the PG"3 MoAb. At APAAP immunoscreening, the supernatant of l of 500 hybridoma colonies produced a speckled nuclear staining on normal human tonsil and U937 cells (Fig 2A) . This murine hybridoma was cloned three times to produce the PG-M3 clone that was used in subsequent studies.
The specificity of the PG-M3 MoAb was analyzed by immunoprecipitation, Western blotting, and immunocytochemistry on COS-l and U937 cells transfected with a PML expression vector. The expressed PML cDNA (PML3 3-4-6-7; Fig 1) encodes for a predicted PML protein of 70,028 kD."
Anti-PG-M3 immunoprecipitates from PML-or mocktransfected COS-l and U937 cells were resolved by SDSpolyacrylamide gel electrophoresis (PAGE) and Western blotted using a polyclonal antibody directed against the PML3 unique carboxy-terminal region (anti-PML3; M. Fagioli, June 1992). An approximately 90-kD anti-PML3 immunoreactive peptide was identified in the anti-PG-M3 immunoprecipitates from PML transiently transfected COS-l and stably transfected U937 cells. No specific anti-PML immunoreactive polypeptides were detected in the anti-PG-M3 immunoprecipitates from mock-transfected COS-l and U937 cells (Fig 3A) .
Western blotting of total lysates from transiently transfected COS-I and stably transfected U937 cells using the PG-M3 MoAb showed an approximately 90-kD immunoreactive polypeptide. No specific anti-PG-M3 immunoreactive polypeptides were detected in the mock-transfected COS-l and U937 cells (Fig 3B) .
At immunocytochemistry, both mock-and PMLtransfected U937 cells displayed a speckled nuclear staining with the PG-M3 MoAb. However, the size of PML nuclear dots was much larger in PML than mock-transfected cells (see for comparison Fig 2A and B) .
Collectively, these data confirm that the PG-M3 MoAb has anti-PML specificity. Identical results were obtained with a rabbit polyclonal anti-PML raised against the same peptide sequence as PG-M3 (data not shown).
Expression of PMLproteins in non-APL and APL cultured cells. All human cell lines tested, including the myeloid cell lines HL60, KG1, TF1, K-562, and U937, exhibited the same nuclear speckled PML positivity not associated with nucleoli (Fig 2A) . A few PML dots were also noted in the cytoplasm of 10% to 20% of cells (Fig 2A) . No association of PML with metaphase chromosomes was observed in mitotic cells.
In contrast, a micropunctate staining pattern consisting of many tiny intranuclear dots (data not shown) was typical of the NB4 promyelocytic cell line bearing the t(15;17)38 (a gift from M. Lanotte, Hopital Saint Louis, Paris, France). The percentage of NB4 cells that manifested cytoplasmic staining for PG-M3 was similar to that of other myeloid and nonmyeloid cell lines (10% to 20%). The nuclei of mouse cell lines showed no PG-M3 reactivity, and a few PG-M3 reactive nuclear dots were seen in monkey COS-l cells (data not shown).
Cellular localization of transfected PML isoforms and the PMURARa protein. From the above results, it appears that normal PML and PML/RARa proteins are localized in both the nucleus (virtually all cultured cells) and the cytoplasm (10% to 20% cells). Because many PML and PML/RARa isoforms have been identified that might differ in thei! cellular localization, we analyzed the staining pattern of different, individually transfected PML isoforms.
Both human (U937) and mouse (NIH-3T3) cells were used as recipients for transfection. As none of our antibodies (PG-M3 and polyclonal) reacted with the nuclei of mouse NIH-3T3 cells under basal conditions, mouse cells appear to be suitable target cells for dissecting the expression of PML or PML/RARa exogenous cDNAs from endogenous anti-PML-reacting proteins. PG-M3 causes a weak, nonspecific cytoplasmic staining of NIH-3T3 cells under basal conditions. For this reason, the polyclonal anti-PML antibody raised against the same peptide as PG-M3 was used to stain transfected NIH-3T3 clones.
Two groups of PML isoforms that, due to alternative assemblage of PML coding exons, differ either in their Cterminal region or in the length of their central region have been identified." The alternative splicing of PML exons that generate the second group of PML isoforms also occurs in the PML/RARa primary transcript." A schematic representation of the different PML isoforms used in this study is shown in Fig 1. Transfection of NIH-3T3 cells with cDNA encoding the PML2 3-4-5-6-7 or PML3 3-4-6-7 isoforms resulted in a strong nuclear staining of all cells with the typical speckled pattern. The PML-stained structures within the nuclei of NIH-3T3 cells were round and large and often had a vescicular-like appearance (Fig 2D) . Moreover, numerous positive dots were evenly distributed throughout the cytoplasm of most cells.
NIH-3T3 cells transfected with cDNA encoding PML3 3-7 showed only cytoplasmic staining that was mainly microgranular with one to two large, sometimes ring-like, spots (Fig 2E) . The staining pattern of mouse NIH-3T3 cells transfected with the cDNA encoding PML 3-4-7 was predominantly, but not exclusively, cytoplasmic and was limited to one to two large dots (Fig 2F) . Similar results were obtained with the U937 cell line transfected with the same cDNAs, with the only difference being that the final staining pattern was both cytoplasmic (predominant positivity due to the product of transfected cDNA) and nuclear (the expected positivity due to endogenous PML; Fig 2C) . NIH-3T3 cells transfected with the MT-PR cDNA and induced to express the PMURARa fusion protein by zinc treatment (see Materials and Methods) showed a microgranular staining pattern consisting of many fine intranuclear dots that were also observed in the cytoplasm of transfected cells. This clearly differed from the speckled pattern of PMLtransfected NIH-3T3 cells and resembled that observed in NB4 cells.
Expression of the PML protein in normal tissues. In normal peripheral blood, the PG-M3 MoAb reacted with all mononuclear cells, with monocytes showing a higher number of nuclear dots (three to five per cell) than neutrophils and lymphocytes (two to three per cell) (data not shown).
Bone marrow myeloid cells at different stages of maturation showed moderate positivity for PML. Cells of the erythroid lineage and megakaryocytes were usually negative (data not shown).
Cell populations in human thymus clearly differed in their content of PML. Cortical thymocytes were PML-negative ( Fig 4A) ; only rare, usually larger, cortical thymocytes reacted with PG-M3. The thymic cortex also contained isolated nonlymphoid elements that showed intense speckled staining for PML (Fig 4A) . Double-staining experiments identified these cells as macrophages (not shown). The amount of PML was greater in medullary than cortical thymocytes; the most strongly PML-positive cells in the medulla were thymic epithelial cells, whose staining pattern resembled that of tonsil epithelium (see below).
Cell populations of human tonsil also showed variable expression of PML proteins. Tonsil T cells contained a few, very distinct PML dots (Fig 4B) as compared with negative cortical thymocytes (Fig 4A) . A staining pattern similar to that of T lymphocytes was seen in mantle B cells, whereas germinal center B cells usually stained weakly (one small nuclear dot per cell) or not at all for PML (Fig 4C) . In contrast, germinal center macrophages exhibited intense nuclear PML staining (Fig 4C) . The second most strongly labeled cell population in the tonsil were endothelial cells ( Fig  4E) and squamous epithelium (not shown). B and T cells in the spleen exhibited a staining pattern similar to that observed in the tonsil. Among B cells, the most intense nuclear dot positivity for PML was seen in the splenic marginal zone B cells (not shown).
PML proteins could also be detected within the nuclei of several nonlymphohematopoietic cells, including hepatocytes, cells of kidney tubules, and epithelia (data not shown).
PML expression in pathologic samples. Staining results similar to those observed in the tonsil were obtained in inflammatory and reactive lymphadenites (follicular hyperplasia, toxoplasmosis, sarcoidosis, Kikuchi's lymphadenitis, etc). Interestingly, the nuclei of activated macrophages from cases of toxoplasmosis (Fig 4D) , Hodgkin's disease, and peripheral T-cell lymphomas showed a very strong nuclear dot positivity for PML. The size of nuclear dots in these cells was similar to that seen in mouse and human PMLtransfected cells. High expression of PML was also observed in cases of squamous cell carcinoma (Fig 4F) .
PML expression during macrophage differentiation and activation. The reported strong positivity for PML of tissue macrophages prompted us to analyze the expression of PML in promonocytic U937 cells after stimulation with agents able to induce monocyte activation or differentiation.
As compared with controls (Fig 5A) , the number of PML dots within the nuclei of U937 cells was greatly increased (peak at day 1) after activation with IFN-y (Fig 5B and C) .
U937 cells incubated with vitamin D3 and/or TGFPl showed clear evidence of maturation (changes in morphology, induction of CD68 and PG-M2 markers, low prolifera- Fig SD-F) . As compared with controls (Fig SA) , PML expression was not significantly changed by incubation with vitamin D3 or TGFPl alone. However, both the number and the size of PG"3-positive nuclear dots were increased after incubation with vitamin D3 plus TGFPl (Fig SD) . Maximum expression of PML was observed when U937 cells were both activated and induced to mature with IFN-7 plus vitamin D3 plus TGFpl (Fig SE) . Collectively, the above results suggest that PML is upregulated during both monocyte maturation and activation.
DISCUSSION
In this report, we describe a new murine MoAb (PG-M3) specifically directed against the aminoterminal portion of the PML protein. The PML epitope recognized by PG-M3 appears to be restricted to the human species, a somewhat surprising finding in the light of the very close sequence homology between human and mouse PML genes (M. Fagioli, September 1993). Immunostaining of fresh samples (cytospins, frozen sections, etc) with the PG-M3 MoAb is the most sensitive test for detecting PML proteins, but cells overexpressing PML are also strongly labeled by the antibody on paraffin sections after microwave heating. The PG-M3 MoAb recognizes both endogenous and overexpressed PML proteins at immunocytochemical analysis, but does not identify the endogenous PML proteins in immunoprecipitation or Western blotting experiments. This might be caused by the large number of expressed PML isoforms (13 so far identified)?3 Currently available anti-PML antibodies may not be sufficiently sensitive to show the small amounts of each PML isoform present after gel electrophoresis separation.
Another MoAb (SE10) has recently been reported to react with PML.20.2L However, 5E10 was originally obtained by immunizing mice with rat liver nuclear matrix and there is not yet conclusive evidence that its specificity is restricted to PML. Immunoblotting of rat liver nuclei and HeLa cells (human cervix carcinoma) with SE10 showed four immunoreactive polypeptides of 149, 126 (the most prominent ones), 95, and 63
This immunoblotting pattern differs in several aspects from that reported for most anti-PML polyclonal antibodies and the PG-M3 MoAb that only react with human PML and do not recognize endogenous PML by immunoblotting. Moreover, the SE10 epitope is lost in some of the PML-RARa forms," and its reactivity pattern in human and animal tissues is unknown. At the present time, therefore, PG-M3 may be regarded as the best characterized anti-PML and anti-PML-RARa MoAb.
PML proteins labeled by PG-M3 localize mainly within the nucleus to give a typical speckled staining pattern. In both mouse NIH-3T3 and human U937 PML-transfected cells, PG-M3 labels nuclear spherical structures that morphologically resemble the so-called nuclear b o d i e~.~~~* '~~~ This speckled pattern clearly differs from the micropunctate staining pattern of PML in the NB4 promyelocytic cell line and NIH-3T3 cells transfected with PML/RARa. This finding is in keeping with reports from other investigators"-" who proposed that the PMLiRARa fusion protein displaces PML from its targeting sites and, thus, plays a role in thepathogenesis of APL.
Granular cytoplasmic labeling for PML is seen in 10% to 20% of cells in all human cell lines stained with PG-M3, including NB4. This is unlikely due to nonspecific diffusion of PML proteins outside the nucleus, a phenomenon sometimes observed in cells not appropriately fixed or after repeated thawinglfreezing of samples (B. Falini, May 1994). In fact, cytoplasmic positivity for PML is always dot-like, while nonspecific cytoplasmic positivity is usually diffuse, and in samples dried overnight and fixed for 10 minutes in acetone, there are no diffusion artefacts with nuclear antigens tested in parallel (eg, Ki-67). The cytoplasmic localization is, therefore, probably a specific property of PML proteins. The dot-like cytoplasmic positivity suggests that PML is associated with discrete cytoplasmic organelles, whose nature needs to be further clarified by immunoelectron microscope studies.
The PML cytoplasmic localization could be due to labeling of physiologically existing PML isoforms (PML3 3-7, PML 3-4-7) that are unable to enter the nucleus. Transfection of two PML isoforms yielded proteins that appeared exclusively (PML3 3-7) or predominantly (PML 3-4-7) in the cytoplasm. Comparison of the amino acid sequence of the PML3 3-7 and PML 3-4-7 isoforms with that of the other PML isoforms suggests that the PML region 466 to S53 is required for PML nuclear localization. This region contains the KRKCSQTQCPRKVIK sequence (amino acids 476 to 490) that, as already pointed out : ' is a candidate nuclear localization signal (NLS). However, despite the existence of cytoplasmic PML isoforms, cytoplasmic localization appears to be a general feature of PML proteins, as NIH-3T3 cells transfected with PML2 3-4-5-6-7 and PML3 3-4-6-7 (able to enter the nucleus) also exhibit cytoplasmic labeling.
Our immunohistologic studies provide the first evidence that PML is variably expressed in normal lymphohematopoietic tissues. PML appears to be preferentially expressed in postmitotic cells, as suggested by an inverse correlation between PML expression and the proliferation-associated antigen Ki-67 (B. Falini, May 1994). In normal tonsil and reactive lymph nodes, the highest content of PML was detected in endothelial cells and macrophages, particularly activated ones. Macrophage expression of PML seems to be upregulated during the process of maturation and activation, as demonstrated by the dramatic increase in the nuclear PML of promonocyte U937 and TI"1 cell lines after S-day in vitro stimulation with agents that induce macrophage maturation (vitamin D3, TGFP1) or activation (IFN-7) . A correlation between PML expression and macrophage activation is further supported by the strong PML positivity in epithelioid histiocytes of toxoplasmosis and viral-or neoplastic-associated hemophagocytic syndromes, all pathologic conditions in which macrophages are known to be highly a~t i v a t e d .~* .~~ The functional role, if any, of PML in the process of maturation and activation of human macrophages is at present unknown and warrants further investigation. The effect of IFN seems to be specific, as other cytokines, such as tumor necrosis factor (TNF), interleukin-l (IL-l), and IL-6 have no effect on PML expression and distribution (P.-G. Pelicci, May 1994). anti-FWRa antibodies. This test is expected to be highly sensitive and specific, as colocalization of the two proteins is a specific property of leukemic promyelocytes. Finally, PG-M3 should allow retrospective analysis of PML expression on microwave-processed routine biopsies from a variety of human neoplasms.
